Reported lifetime breast cancer risks for women with LFS range up to 80–90%, surpassing the risk linked to BRCA1- and BRCA2-related hereditary breast cancer [57, 59], whereas ESMO guidelines indicate a substantially lower lifetime risk of around 40% [22]. This evidence concerns the gene BRCA2 and breast carcinoma.